{"filing":{"accession_number":"0001193125-26-270275","cik":"0001907108","ticker":"LXEO","company_name":"Lexeo Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-15","report_date":null,"primary_document":"lxeo-20260615.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1907108/000119312526270275/lxeo-20260615.htm"},"events":[{"id":10888,"run_id":9551,"accession_number":"0001193125-26-270275","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"Lexeo Therapeutics announced material regulatory updates regarding LX2006 for Friedreich ataxia cardiomyopathy, including pivotal study design to support accelerated approval pathway. This represents significant clinical and regulatory progress for the company's gene therapy candidate.","company_name":"Lexeo Therapeutics, Inc.","ticker":"LXEO","filing_date":"2026-06-15","form":"8-K","submitted_at":null,"items":[{"id":7317,"accession_number":"0001193125-26-270275","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.75,"reasoning":"This Item 7.01 disclosure is a routine Regulation FD notice of a corporate presentation to be used in a webcast (referenced in Item 8.01). The filing contains only a boilerplate safe-harbor statement and does not disclose substantive business information, financial results, or material events. Without knowledge of the webcast content itself, this appears to be an administrative disclosure of presentation materials rather than a material event triggering disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T11:07:08.829362+00:00","company_name":"","ticker":null,"filing_date":""},{"id":7318,"accession_number":"0001193125-26-270275","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The disclosure announces regulatory updates to LX2006 for Friedreich ataxia cardiomyopathy, including pivotal study design to support accelerated approval. This represents material clinical/regulatory progress for a gene therapy candidate that would affect investor assessment of the company's pipeline and regulatory pathway, but does not fit neatly into the more specific event categories (not an earnings release, M\u0026A activity, impairment, or litigation). The forward-looking statements and cautionary language underscore the significance of the regulatory milestone being communicated.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T11:07:08.829362+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7317,"accession_number":"0001193125-26-270275","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.75,"reasoning":"This Item 7.01 disclosure is a routine Regulation FD notice of a corporate presentation to be used in a webcast (referenced in Item 8.01). The filing contains only a boilerplate safe-harbor statement and does not disclose substantive business information, financial results, or material events. Without knowledge of the webcast content itself, this appears to be an administrative disclosure of presentation materials rather than a material event triggering disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T11:07:08.829362+00:00","company_name":"Lexeo Therapeutics, Inc.","ticker":"LXEO","filing_date":"2026-06-15"},{"id":7318,"accession_number":"0001193125-26-270275","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The disclosure announces regulatory updates to LX2006 for Friedreich ataxia cardiomyopathy, including pivotal study design to support accelerated approval. This represents material clinical/regulatory progress for a gene therapy candidate that would affect investor assessment of the company's pipeline and regulatory pathway, but does not fit neatly into the more specific event categories (not an earnings release, M\u0026A activity, impairment, or litigation). The forward-looking statements and cautionary language underscore the significance of the regulatory milestone being communicated.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T11:07:08.829362+00:00","company_name":"Lexeo Therapeutics, Inc.","ticker":"LXEO","filing_date":"2026-06-15"}]}